Skip to main content
OpenTrials
Completed

NCT Number: NCT02358993

Short-course Methenamine Hippurate for Prevention of Post-operative UTI

The investigators will determine the efficacy of an innovative short regimen of methenamine hippurate on prevention of post-operative UTI in patients requiring short-term catheterization after pelvic reconstructive surgery through a single-blind, randomized controlled trial. Primary outcome will be the rate of symptomatic UTI within 3 weeks of catheter removal. The investigators will study cost-effectiveness, antibiotic resistance profiles, and adverse drug effects. Findings may reduce antibiotic use and nosocomial UTIs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Chestnut Hill Hospital, Philadelphia, Pennsylvania, United States

Loading trial locations.

About this study

Prevention of post-operative urinary tract infections (UTI) is becoming important for both the individual patient and the health system. Complications of UTI include pyelonephritis and bacteremia, requiring hospitalization and parenteral antibiotics. Additionally, recurrent exposure to antibiotics commonly given for UTIs increases the risk of antibiotic resistance to uropathogens. UTIs also increase economic burdens on the health care system, with each episode costing nearly 600 dollars. UTIs associated with catheterization are particularly costly for hospitals, resulting in decreased hospital quality measures and lack of compensation.

This is particularly important after pelvic reconstructive surgery, as reported rates of UTI reach up to 20-25%. Urinary retention requiring short-term indwelling catheterization, common in these women, contributes to the risk of UTIs by increasing the risk of bacteriuria by 5-10% per day and through the dislodging of bacterial colonies during catheter removal. Balancing prevention and resistance and cost is key. A meta-analysis by Marschall et al indicated the benefit of a short dose of antibiotic prophylaxis at catheter removal in general post-surgical patients. However, data is lacking on the effects of daily antibiotic prophylaxis on resistance and cost.

A possible alternative to antibiotics presents itself in methenamine hippurate, a urinary antiseptic which forms formaldehyde in the presence of acidic urine. It is relatively inexpensive, and does not induce resistance in vivo. Prior studies have shown that daily use of methenamine can decrease the risk of post-operative UTI.

The purpose of our study was to investigate the efficacy of a short course of methenamine hippurate at catheter removal to that of a short course of ciprofloxacin in prevention of UTIs after short-term indwelling catheterization. Additionally, we investigated factors that influence post-operative UTIs, the rate of culture-proven UTIs after prophylaxis, the antibiotic resistance profile of those undergoing prophylaxis, and the cost effectiveness of prophylaxis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • female;
  • patients who are able to read and write English;
  • 18 years of age or older;
  • underwent surgery for pelvic organ prolapse, urinary incontinence, or both;
  • require post-operative short-term transurethral catheterization for greater than 24 hours.

Exclusion criteria

  • patients undergoing surgical intervention for sacral neuromodulation, or mesh excision;
  • patients requiring long-term catheterization secondary to injury to the urinary tract;
  • patients who pass their post-operative trial void and thus, do not require additional catheterization;
  • patients requiring catheterization for less than 24 hours;
  • pregnant patients;
  • patients who are breast-feeding;
  • allergy to methenamine hippurate or fluroquinolones (either ciprofloxacin or levofloxacin);
  • impaired renal or hepatic function;
  • pre-operative urinary retention;
  • patients who are currently using sulfonamides;
  • patients who have severe dehydration;
  • patients using tizanidine;
  • patients sensitive to quinolones class;
  • patients using theophylline; patients with myasthenia gravis;
  • patients with prolongation of QT interval.

Treatment and study plan

Methenamine Hippurate

Drug

A urinary antiseptic used for prevention of UTI

Other names: Hiprex

Ciprofloxacin

Drug

An antibiotic used for treatment and prevention of UTI

Other names: Cipro

Primary outcomes

  1. Treatment of Clinically Suspected UTI - Using Intent to Treat Analysis

    Time frame: 3 weeks post-operative

    This is defined as any symptomatic UTI requiring treatment with antibiotics as determined by the development of 2 or more of the following symptoms, in the absence of vaginal symptoms: urinary frequency; urinary urgency; dysuria; fever over 38oC/100.4oF; suprapubic, flank, or back pain; and/or chills.

  2. Treatment of Clinically Suspected UTI - Per Protocol

    Time frame: 3 weeks post-operative

    This is defined as any symptomatic UTI requiring treatment with antibiotics as determined by the development of 2 or more of the following symptoms, in the absence of vaginal symptoms: urinary frequency; urinary urgency; dysuria; fever over 38oC/100.4oF; suprapubic, flank, or back pain; and/or chills.

Secondary outcomes

  1. Number of Participants With Culture-positive Symptomatic UTI

    Time frame: 3 weeks post-operative

    All patients will be encouraged to submit urine cultures prior to treatment, but this is not always possible. Amongst patients who undergo urine culture as part of standard of care for UTI, the rate of positive cultures will be identified.

  2. Antibiotic Resistance of Culture-positive Symptomatic UTI

    Time frame: 3 weeks post-operative

    All patients who submit urine cultures that are positive will have sensitivities performed as per standard care. The prevalence of bacterial species and sensitivities will be collected

  3. Cost-effectiveness of Prophylaxis With Methenamine Hippurate for Prevention of Post-operative UTI Compared to Prophylaxis With Fluoroquinolones

    Time frame: 3 weeks post-operative

    Routine costs of prevention of UTI with methenamine hippurate prophylaxis will be compared with costs of prevention of UTI with fluoroquinolone prophylaxis. We plan to capture costs for each direct medical service use, direct non-medical items, and indirect items related to post-operative UTIs in each arm of the trial.

  4. Prevalence of Side Effects

    Time frame: within 24 hours of administration

    Adverse effects from the administration of methenamine and fluoroquinolones will be collected.

Other outcomes

  1. Rate of UTI Consistent With NHSN Criteria

    Time frame: 3 weeks post-operative

    We plan to analyze the prevalence of UTI in this population that meet the definitions of symptomatic UTI and catheter-associated UTI according to the National Healthcare Safety Network criteria.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Official study title

The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection

Acronym: NO-UTI

Important dates

Study start
2014
Primary completion
2020
Study completion
2020
First posted
Feb 9, 2015
Registry last updated
Feb 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.